Trial Profile
An intergroup phase III trial of Ramucirumab plus Irinotecan in third or more line Beyond progression after Ramucirumab for Advanced Gastric cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Irinotecan
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms RINDBeRG
- 20 Jan 2024 Results of subgroup analysis of the effect of ramucirumab in pretreatment with immune checkpoint inhibitor nivolumab presented at the 2024 Gastrointestinal Cancers Symposium.
- 24 Oct 2023 Primary endpoint (Overall survival (OS)) has not been met, as per results presented at the 48th European Society for Medical Oncology Congress.
- 24 Oct 2023 Results (From February 2019 to August 2022) assessing primary efficacy and safety of ramucirumab plus irinotecan with irinotecan in advanced gastric cancer patients, presented at the 48th European Society for Medical Oncology Congress.